TrialHaematologica2023

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.

Francesca R Mauro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.